Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 11/20 | 0.85 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1729548 | 0.93 | F2R (0.93) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL14449192 | 0.92 | F2R (0.85) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| Atopaxar SCHEMBL30175034 | 0.92 | F2R (1.00) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| Atopaxar SCHEMBL1730339 | 0.92 | F2R (1.00) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1728795 | 0.92 | F2R (0.84) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| Atopaxar SCHEMBL1729065 | 0.91 | F2R (0.98) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| Atopaxar SCHEMBL1728925 | 0.91 | F2R (1.00) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| Atopaxar SCHEMBL30008036 | 0.91 | F2R (1.00) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| Atopaxar SCHEMBL29904776 | 0.91 | F2R (1.00) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 | |
| Bromide SCHEMBL1730058 | 0.89 | F2R (0.88) | F2RGAAALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062239-A1 | THROMBIN RECEPTOR ANTAGONISTS AS PROPHYLAXIS TO COMPLICATIONS FROM CARDIOPULMONARY SURGERY | SCHERING CORPORATION | 2009-03-05 | — | — | US | disclosed |
| US-20080234236-A1 | REDUCTION OF ADVERSE EVENTS AFTER PERCUTANEOUS INTERVENTION BY USE OF A THROMBIN RECEPTOR ANTAGONIST | SCHERING CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080194560-A1 | DISINTEGRATION PROMOTERS IN SOLID DOSE WET GRANULATION FORMULATIONS | SCHERING CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080152712-A1 | RAPIDLY DISINTEGRATING LYOPHILIZED ORAL FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | SCHERING CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-20080031943-A1 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | TOPROL ACQUISITION LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080026050-A1 | SOLID DOSE FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20070238674-A1 | TRA COMBINATION THERAPIES | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070202140-A1 | THROMBIN RECEPTOR ANTAGONISTS AS PROPHYLAXIS TO COMPLICATIONS FROM CARDIOPULMONARY SURGERY | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194560-A1 | DISINTEGRATION PROMOTERS IN SOLID DOSE WET GRANULATION FORMULATIONS | SP1, TMPRSS2, GPR39 | F2R 11/4885GAA 2183/4885ALDH1A1 4610/4885 |
| US-20080234236-A1 | REDUCTION OF ADVERSE EVENTS AFTER PERCUTANEOUS INTERVENTION BY USE OF A THROMBIN RECEPTOR ANTAGONIST | PTAFR, F2R, F2RL3 | F2R 2/4885GAA 2731/4885ALDH1A1 4030/4885 |
| US-20080152712-A1 | RAPIDLY DISINTEGRATING LYOPHILIZED ORAL FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | F2R, F2RL1, PLAT | F2R 1/4885GAA 1711/4885ALDH1A1 4549/4885 |
| US-20080026050-A1 | SOLID DOSE FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | F2R, F2RL1, TBXA2R | F2R 1/4885GAA 4441/4885ALDH1A1 3702/4885 |
| US-20090062239-A1 | THROMBIN RECEPTOR ANTAGONISTS AS PROPHYLAXIS TO COMPLICATIONS FROM CARDIOPULMONARY SURGERY | F2R, CPB2, TFPI | F2R 1/4885GAA 2937/4885ALDH1A1 2106/4885 |
| US-20080031943-A1 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | F2R, F2RL1, TBXA2R | F2R 1/4885GAA 2313/4885ALDH1A1 4276/4885 |
| US-20070202140-A1 | THROMBIN RECEPTOR ANTAGONISTS AS PROPHYLAXIS TO COMPLICATIONS FROM CARDIOPULMONARY SURGERY | F2R, CPB2, TFPI | F2R 1/4885GAA 2937/4885ALDH1A1 2106/4885 |
| US-20070238674-A1 | TRA COMBINATION THERAPIES | EDNRA, EDNRB, TBXA2R | F2R 9/4885GAA 2281/4885ALDH1A1 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.